DaVita Clinical Research Expands Capabilities with Investments in Central Laboratory
June 09 2011 - 9:00AM
Business Wire
DaVita Clinical Research® (DCR®), a provider of clinical
research services focused on kidney research as well as a multitude
of specialty therapeutic populations, today announced the company’s
recent investment in its Central Laboratory, servicing
pharmaceutical, biotechnology and medical device industries.
The investment was applied to analytical methodology,
information technology (IT) and instrumentation in support of DCR’s
continued drive to serve its clients. Over the past three years,
DCR has had a strategic focus on Central Laboratory services,
investing in state-of-the-art capital equipment, infrastructure and
laboratory expansion/remodeling. The investment was placed in DCR’s
Central Laboratory to ensure continuous delivery of customized care
and satisfaction to its patients.
The Central Laboratory uses the latest in laboratory
instrumentation to provide rapid, accurate results. Some examples
of the lab’s instrumentation and ever-increasing test menu
include:
- 7 Olympus 5400
- 17 Siemens Centaur
- 9 Tosoh G-8
- 2 Liaison Diasorin
- 8 Perkin-Elmer ICP-MS
- 2 Nova
- 2 Dianex
- 23 Siemens Advia 2120
- 2 TOPS Coagulation
- 19 BACTEC 9240
- 14 Lonza BioTek
- 4 Vitek-2
DCR’s Central Laboratory also has invested in such technology as
centrifuges, auto samplers, slide strainers, incubators, biosafety
cabinets and decappers. DCR’s investment assisted in expanding and
remodeling the laboratory, adding significant space to help
facilitate future service expansion. In addition, extensive
investment in its Falcon LabTM software application has resulted in
the latest release, which includes an industry-leading report
package.
At DCR’s Central Laboratory, individual trial samples are
tracked using LabScope Online®, a leading-edge order-entry and
reporting system designed to streamline lab processes while
maintaining strict quality assurance. Additional services include
the new, innovative green packaging capabilities featuring a unique
IATA-compliant, storage-friendly design, and the lab’s highly
dedicated customer support team, which ensures most specimen
turnaround time of 24 hours or less.
“DCR’s Florida-based Central Laboratory facility is one of the
industry’s best kept secrets,” said DCR Vice President, Commercial
Development Kevin J. Goudreau. “We are confident that, over time,
our continued investments in both physical assets and an expanded
assay list will position us to be a prominent player in the
clinical trials support business.”
The DCR Central Laboratory team is led by experienced medical
technologists, medical technicians and clinical pathologists, and
receives formal guidance from top nephrologists in the
industry.
DaVita, DaVita Clinical Research, DCR and Falcon Lab are
trademarks or registered trademarks of DaVita, Inc. All other
trademarks are the property of their respective owners.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR) is committed to advancing the
knowledge and practice of kidney care. DCR brings unsurpassed
knowledge, skill, and expertise to pharmaceutical research,
facilitating the success of their clients’ clinical trials. DCR’s
clinical expertise ranges from designing the study to preparing and
submitting the final report. DCR’s Early Clinical Research unit
(Phase I-IIa) and Clinical Development network of physicians and
investigative sites, Health Economics and Central Laboratory are
focused on providing world-class clinical research in both
complex/specialty populations and therapeutic areas as well as CKD
and ESRD populations needed to meet clinical goals. To learn more
about DCR, visit www.davitaclinicalresearch.com.
About DaVita
DaVita Inc., a Fortune 500® company, is a leading provider of
kidney care in the United States, delivering dialysis services and
education to patients with chronic kidney failure and end stage
renal disease. As of March 31, 2011, DaVita operated or provided
administrative services at 1,642 dialysis facilities, serving
approximately 128,000 patients. DaVita develops, participates in
and donates to numerous programs dedicated to transforming
communities and creating positive, sustainable change for children,
families and our environment. The company’s leadership development
initiatives and corporate social responsibility efforts have been
recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu,
among others. For more information, please visit
www.davita.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From May 2024 to Jun 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2023 to Jun 2024